
Tempest Therapeutics: A global biotech firm developing targeted, immune-mediated anti-tumor therapies.
Tempest Therapeutics, founded with a core mission to develop innovative cancer therapies, focuses on modulating anti-tumor immunity pathways. The company is dedicated to creating first-in-class oral drug therapeutics with broad potential benefits for cancer patients. By exploring both new and validated pathways, Tempest aims to discover and develop novel treatments that can significantly impact the global fight against cancer.
Notable figures affiliated with Tempest Therapeutics include experienced leaders in biotechnology and oncology. The company has attracted significant investment from leading venture capital firms, which has enabled it to advance its research and development efforts. Key achievements include the successful progression of its drug candidates through various stages of clinical trials, demonstrating promising results. Overall, Tempest Therapeutics is making a substantial impact in the field of cancer treatment, offering hope to patients worldwide through its pioneering therapies.

PineTree Therapeutics
pinetreetx.com

Terpenoid Therapeutics

Window Therapeutics
windowtx.com

Fuse Biotherapeutics
fusebiotx.com

Thetis Pharmaceuticals
thetispharma.com

Nimbus Therapeutics
nimbustx.com

Tango Therapeutics
tangotx.com

Tizona Therapeutics
tizonatx.com

LTZ Therapeutics

Checkpoint Therapeutics
checkpointtx.com

Vivace Therapeutics

Angarus Therapeutics
angarustx.com

Telo Therapeutics

Palm Therapeutics

Meditope Biosciences
meditope.com
Companies similar to Tempest Therapeutics include PineTree Therapeutics, Terpenoid Therapeutics, Window Therapeutics and Fuse Biotherapeutics.
Tempest Therapeutics was founded in 2011.
Tempest Therapeutics' headquarters is located in South San Francisco, CA, US.
Tempest Therapeutics' most recent funding round was for $15M (USD) in April 2022.
As of Apr 27, 2022, Tempest Therapeutics has raised a total of $90M (USD).